Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
NCT00940004
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
autologous dendritic cell vaccination
Sponsor
Radboud University Medical Center